Gibson Oncology, LLC
PrivateLast Round
VC Round
Jul 21, 2025
Total Funding Raised
$4.05M
Company Overview
Gibson Oncology, LLC is a biotechnology company that develops novel small molecule compounds for cancer therapy, focusing on dual inhibitors of topoisomerase I (TOP1) and the cMyc oncogene.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gibson Oncology, LLC Comparables
Compare Gibson Oncology, LLC with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Peel Therapeutics | 81% | |
| Hemispherian AS | 79% | |
| Global Cancer Technology, Inc. | 79% | |
Gibson Oncology, LLC Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jul 21, 2025 | ||||
| Seed | Oct 17, 2024 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 1, 2026
Monthly visitors grew 2001% MoM, from 79 to 1.7K.
Gibson Oncology, LLC Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Gibson Oncology, LLC's valuation, stock price, and market status.